Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     

  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     

  • Bitcoin GBP

    51,166.59
    +445.09 (+0.88%)
     

  • CMC Crypto 200

    1,372.79
    +60.16 (+4.58%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

United States Human Vaccines Market Report 2022: A Market Poised to Grow by $31.51 Bn by 2028 Featuring Sanofi Pasteur, Merck, Pfizer, Seqirus, AstraZeneca, Dynavax Technology, Emergent BioSolutions

Research and Markets
·6-min read
Company Logo
Company Logo

U.S. Influenza Vaccines Market

U.S. Influenza Vaccines Market
U.S. Influenza Vaccines Market

Dublin, June 27, 2022 (GLOBE NEWSWIRE) -- The "United States Human Vaccines Market Size, Share, Top 45 Human Vaccines Brand In-depth Analysis, Emerging Trends, Current Analysis, Growth, Demand, Opportunity, and Forecast 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.

Amid the COVID-19 crisis, the United States human vaccines market is poised to grow by US$ 31,517 million by 2028, accelerating at a CAGR of 7% during the forecast period.

The report contains a deep analysis of the United States human vaccines market size in terms of value. The report provides a clear insight into current and future developments of the United States vaccines market.

ADVERTISEMENT

The report also explores the detailed analysis, insights of the top 45 vaccines market assessment in the United States from 2018 to 2021, and forecasts to 2028. The report also details the latest information about the vaccine's pricing analysis, insights, and trends, and the regulatory framework of the United States human vaccines market.

After conducting thorough research on the historical and current growth parameters, the growth prospects of the United States human vaccines market are obtained with maximum precision.

This new 2022 market report provides a holistic analysis of the entire United States human vaccines market. The report offers the most up-to-date industry data on the actual market situation and future outlook for the United States' human vaccines market.

The report also tracks and analyses competitive developments, including collaboration, partnership deals, distribution, exclusive and licensing agreements, new vaccine developments, and R&D activities in the market. The report also delivers an in-depth analysis of evolving market trends, drivers, and restraining forces that influence the growth of the market.

The report also analyses detailed profiles of innovative and leading players with information on business overview, companies' vaccines portfolio, promising vaccines in the clinical development, and the newest developments

The report will serve as a source for a 360-degree analysis, thoroughly integrating different models.

The prominent factors that are expected to contribute to the growth of the United States human vaccines market:

  • Increased Disease Awareness

  • Approval/launches of the New Vaccines

  • Rising Focus on Immunization Programs

  • Increasing Investments and Government Support for the Vaccines Development

This Newest and Comprehensive the United States Human Vaccines Market Research Report 2022 Delivers:

  • Comprehensive Research Methodology of the United States Human Vaccines Market

  • Detailed and Extensive Market Overview with Key Analyst Insights

  • Insights about Market Determinants that are Stimulating the United States Human Vaccines Market

  • To Analyze the Historical Growth in the Market Size of the United States Human Vaccines Market from 2018 to 2021

  • To Estimate and Forecast the Market Size of the United States Human Vaccines Market from 2022 to 2028 and Growth Rate until 2028

  • Detailed Insights of the Top 45 Human Vaccines Market Value Used in the U.S. with Six Years Forecast

  • An Insightful Analysis of the Top 45 Vaccines Brand Market Share and Y-o-Y Growth Rate

  • Delivers All-inclusive Insights on the Latest Pricing Analysis, Insights, and Trends

  • Delivers an In-Depth Analysis of Evolving Market Trends, Drivers, and Restraints of the United States Human Vaccines Market

  • An Insightful Investigation has been done on Promising Human Vaccines in the Clinical Development

  • Delivers Comprehensive Insights into the Regulatory Framework of the United States Human Vaccines Market

  • Tracks Competitive Developments, Approaches, Recent Industry Developments, Partnership, Collaboration Deals, Distribution, Exclusive, and Licensing Agreement

  • A Comprehensive List of the Leading Companies along with the Analysis of their Current Vaccines Portfolio, Promising Human Vaccines in the Clinical Development, and Present Development

The Report Helps Answer the Following Questions:

  • What is the current scenario of the United States human vaccines market?

  • What is the total market size and forecast (until 2028) of the United States human vaccines market?

  • How big is the United States human vaccines market?

  • At what CAGR is the U.S. human vaccines market projected to grow in the forecast period (2022-2028)?

  • What are the leading human vaccines? What are their revenue potentials to 2028?

  • Which human vaccine brand provides the highest market share?

  • What is the regulatory framework in the United States vaccines market?

  • What are the key factors driving the United States human vaccines market?

  • What are the key challenges of the United States human vaccines market?

  • What are the major deals and agreement happenings in the United States human vaccines market?

  • What are the United States human vaccines pricing trends and analysis?

  • What are the various human vaccines available in the United States?

  • Who are the topmost market players? What are their happenings, current developments, and scenarios?

  • How is the market predicted to develop in the future?

Key Topics Covered:

1. Executive Summary

2. United States Human Vaccines Market Size and Forecast (2018 - 2028)

3. United States Human Vaccines Brand Market Share and Y-o-Y Growth (%), 2018 - 2028

4. Key Market Growth Drivers and Challenges in the United States Human Vaccines Market
4.1 Key Market Growth Drivers
4.2 Key Market Challenges

5. United States Top 45 Human Vaccines Market Value Analysis, Insights and Forecasts, 2018 - 2028
5.1 Daptacel
5.2 Quadracel
5.3 Kinrix
5.4 Vaxelis
5.5 IPOL
5.6 Vaqta
5.7 Havrix
5.8 Twinrix
5.9 Engerix B
5.10 PedvaxHIB
5.11 ActHIB
5.12 Hiberix
5.13 MenQuadfi
5.14 Tenivac
5.15 Imovax
5.16 FluMist Quadrivalent
5.17 Prevnar 13
5.18 Gardasil 9
5.19 Fluzone Quadrivalent
5.20 Flublok
5.21 Flucelvax Quadrivalent
5.22 Afluria Quadrivalent
5.23 Fluad
5.24 Varivax
5.25 Menactra
5.26 Proquad
5.27 Pneumovax 23
5.28 Fluarix
5.29 FluLaval
5.30 M-M-R II
5.31 Adacel
5.32 Boostrix
5.33 Bexsero
5.34 Menveo
5.35 Trumenba
5.36 Shingrix
5.37 Pentacel
5.38 Recombivax HB
5.39 Rotateq
5.40 Rotarix
5.41 Pediarix
5.42 Infanrix
5.43 Heplisav-B
5.44 TDVAX
5.45 BioThrax
5.46 Other Vaccines

6. United States Human Vaccines Pricing Analysis, Insights and Trends

7. Regulatory Framework of the United States Human Vaccines Market

8. Major Deals and Agreement Happenings in the Human Vaccines Market
8.1 Merger & Acquisitions
8.2 Collaboration Deals
8.3 Licensing Agreement
8.4 Exclusive Agreement
8.5 Distribution Agreement
8.6 Partnership Deals

9. Leading Companies in the United States Human Vaccines Market
9.1 Sanofi Pasteur
9.1.1 Business Overview
9.1.2 Human Vaccines Portfolio
9.1.3 Promising Human Vaccines in the Clinical Development
9.1.4 Recent Development
9.3 Merck
9.4 Pfizer
9.5 Seqirus (CSL Limited)
9.6 AstraZeneca
9.7 Dynavax Technologies Corporation
9.8 Emergent BioSolutions Inc.

For more information about this report visit https://www.researchandmarkets.com/r/pzc3pc

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900